Study Condition(s): Early Symptoms of Alzheimer's Disease
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
Study Alias: LMDC
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
o Participants must have gradual and progressive change in memory function for >6 months o Participants must have a family member or close friend who is with participant at least 10 hours per week and can attend study appointments o Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study o Participants must not have serious or unstable illness that could interfere with the analysis of the study or have a life expectancy <24 months o Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread o Participants must not have serious risk for suicide o Participants must not have history of drug or alcohol use disorder within the last 2 years o Participants must not have multiple severe drug allergies o Participants must not have HIV, Hepatitis B or Hepatitis C